KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Assets Average (2018 - 2026)

Aquestive Therapeutics has reported Assets Average over the past 8 years, most recently at $162.0 million for Q4 2025.

  • For Q4 2025, Assets Average rose 53.27% year-over-year to $162.0 million; the TTM value through Dec 2025 reached $162.0 million, up 53.27%, while the annual FY2025 figure was $130.9 million, 64.85% up from the prior year.
  • Assets Average for Q4 2025 was $162.0 million at Aquestive Therapeutics, up from $128.6 million in the prior quarter.
  • Over five years, Assets Average peaked at $162.0 million in Q4 2025 and troughed at $54.1 million in Q3 2022.
  • A 5-year average of $82.1 million and a median of $64.0 million in 2021 define the central range for Assets Average.
  • Biggest five-year swings in Assets Average: skyrocketed 108.94% in 2024 and later dropped 20.72% in 2025.
  • Year by year, Assets Average stood at $63.6 million in 2021, then fell by 14.43% to $54.5 million in 2022, then increased by 7.3% to $58.4 million in 2023, then skyrocketed by 80.88% to $105.7 million in 2024, then skyrocketed by 53.27% to $162.0 million in 2025.
  • Business Quant data shows Assets Average for AQST at $162.0 million in Q4 2025, $128.6 million in Q3 2025, and $98.0 million in Q2 2025.